Adial Pharmaceuticals, Inc. (ADIL)
After hours:
| Previous close | 2.1700 |
| Open | 2.0400 |
| Bid | 1.9000 x 100 |
| Ask | 2.0000 x 100 |
| Day's range | 1.8700 - 2.1800 |
| 52-week range | 0.7700 - 14.0000 |
| Volume | |
| Avg. volume | 6,461,722 |
| Market cap | 7.826M |
| Beta (5Y monthly) | 1.53 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.9100 |
| Earnings date | 10 May 2024 - 14 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 17.00 |
GlobeNewswireAdial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder
Findings underscore the liver safety of AD04 as compared to placebo in the prior Phase 3 clinical trialGLEN ALLEN, Va., April 10, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the publication of a peer-reviewed article highlighting the promising clinical results, strong safety profile and high c
- GlobeNewswire
Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business Update
Received Favorable Feedback from US and EU Regulatory Agencies Advancing Discussions with Potential Strategic Partners Received $4.3 Million in Gross Proceeds from Warrant Exercises Subsequent to Year-End 2023 GLEN ALLEN, Va., April 02, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a
ZacksIs Masimo (MASI) Outperforming Other Medical Stocks This Year?
Here is how Masimo (MASI) and Adial Pharmaceuticals, Inc. (ADIL) have performed compared to their sector so far this year.
